RCM
GYRE icon

Requisite Capital Management’s Gyre Therapeutics GYRE Stock Holding History

Requisite Capital Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-4,333
Closed -$256K – 215
2018
Q4 		$256K Buy
+4,333
New +$320K 0.1% 51

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Requisite Capital Management's GYRE Position: Q1 2019 in Review

Requisite Capital Management sold out of Gyre Therapeutics (GYRE) in Q1 2019, closing a stake of 4,333 shares — an estimated $256K sold.

Requisite Capital Management first reported a position in GYRE in Q4 2018 and held it in 1 quarter. The position peaked at $256K in Q4 2018. 63 funds tracked by Wall St. Rank hold GYRE as of Q1 2019.

  • Requisite Capital Management reported no remaining Gyre Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Requisite Capital Management sold 4,333 Gyre Therapeutics shares in Q1 2019, an estimated $256K.
  • Requisite Capital Management first reported a position in Gyre Therapeutics in Q4 2018 and held it in 1 quarter.
  • Requisite Capital Management's Gyre Therapeutics position peaked at $256K in Q4 2018.
  • 63 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2019.

Based on Requisite Capital Management's 13F filing for Q1 2019, filed 15 May 2019.